- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CITIUS ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 18.08. | Citius Oncology: LYMPHIR Vial Orders Rise 31% To 926 As 44 Institutions Adopt Drug And July Sets Record | 2 | pulse2.com | ||
| 17.08. | Citius Oncology GAAP EPS of -$0.08 beats by $0.11, revenue of $1.5M misses by $4.27M | 1 | Seeking Alpha | ||
| 14.08. | Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | 406 | PR Newswire | $7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR® launch progresses
Strong institutional demand drives growth in total vials ordered... ► Artikel lesen | |
| 12.08. | Citius Oncology appoints Jonathan Peri to board of directors | 1 | Investing.com | ||
| 05.08. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Citius Oncology, Inc.: Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment | 252 | PR Newswire | New institutional accounts ordering LYMPHIR increased 78% quarter over quarter
LYMPHIR's near-universal payer coverage expands market access
Initial cutaneous T-cell... ► Artikel lesen | |
| 21.07. | Citius Oncology expands sales team for LYMPHIR launch | 1 | Investing.com | ||
| 21.07. | Citius Oncology, Inc.: Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption | 331 | PR Newswire | Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August
CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius... ► Artikel lesen | |
| 01.06. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 01.06. | Citius Oncology presents study data on LYMPHIR combination | 1 | Investing.com | ||
| 01.06. | Citius Oncology, Inc.: Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies | 195 | PR Newswire | Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable... ► Artikel lesen | |
| 26.05. | Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation | 2 | Investing.com | ||
| 15.05. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | 894 | PR Newswire |
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR® launch progressesUp to $36.5 million in debt and equity capital securedBroad payer coverage... ► Artikel lesen | |
| 06.05. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | - | SEC Filings | ||
| 28.04. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Citius Oncology, Inc.: Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development | 374 | PR Newswire | Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration
CRANFORD, N.J., March 31... ► Artikel lesen | |
| 10.03. | Citius Oncology, Inc.: Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers | 773 | PR Newswire | Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy
Topline... ► Artikel lesen | |
| 04.03. | Citius Oncology, Inc.: Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma | 852 | PR Newswire | Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 54,90 | -0,72 % | BB Biotech: KI verändert das Wie, nicht das Was | BB Biotech verbindet seit mehr als 30 Jahren wissenschaftliche Expertise mit einem konsequenten Investmentansatz im Biotechnologiesektor. Mit künstlicher Intelligenz entwickelt das Unternehmen diesen... ► Artikel lesen | |
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| VALNEVA | 2,863 | +1,02 % | Valneva-Aktie im Check am 20.09. (10:36 Uhr): Meine aktuelle Lageeinschätzung | ||
| AMGEN | 335,15 | -0,16 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| EPIGENOMICS | 0,900 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| STRYKER | 238,70 | -0,29 % | Stryker: Cyberangriff wirkt nach - das ist jetzt entscheidend | ||
| BIOFRONTERA | 2,360 | -3,28 % | Biofrontera erhält FDA-Zulassung für Hautkrebsbehandlung | ||
| HEIDELBERG PHARMA | 2,470 | -0,40 % | Heidelberg Pharma AG-Aktie im Check am 18.09. (08:39 Uhr): Meine aktuelle Lageeinschätzung | ||
| ILLUMINA | 210,00 | +0,70 % | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,155 | -0,17 % | CRISPR Therapeutics auf Morgan Stanley Konferenz: Pipeline-Erweiterung und kommerzielle Fortschritte | ||
| BIOXXMED | 1,100 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| OCUGEN | 0,927 | -0,11 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,077 | +9,40 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| CLINUVEL | 5,022 | -1,26 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting |
CITIUS ONCOLOGY INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,120 Euro und damit -1,75 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CITIUS ONCOLOGY INC finden Sie auf Wallstreet Online.